Literature DB >> 15994200

Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases.

Hye Sook Jung1, Dong Wook Kim, Young Suk Jo, Hyo Kyun Chung, Jung Hun Song, Jong Sun Park, Ki Cheol Park, Su Hyeon Park, Jung Hwan Hwang, Ki-Won Jo, Minho Shong.   

Abstract

Papillary thyroid carcinoma (PTC) is a heterogenous disorder characterized by unique gene rearrangements and gene mutations that activate signaling pathways responsible for cellular transformation, survival, and antiapoptosis. Activation of protein kinase B (PKB) and its downstream signaling pathways appears to be an important event in thyroid tumorigenesis. In this study, we found that the thyroid-specific oncogenic RET/PTC tyrosine kinase is able to phosphorylate PKB in vitro and in vivo. RET/PTC-transfected cells showed tyrosine phosphorylation of endogenous and exogenous PKB, which was independent of phosphorylation of T308 and S473 regulated by the upstream kinases phosphoinositide-dependent kinase-1 and -2, respectively. The PKB Y315 residue, which is known to be phosphorylated by Src tyrosine kinase, was also a major site of phosphorylation by RET/PTC. RET/PTC-mediated tyrosine phosphorylation results in the activation of PKB kinase activity. The activation of PKB by RET/PTC blocked the activity of the forkhead transcription factor, FKHRL1, but a Y315F mutant of PKB failed to inhibit FKHRL1 activity. In summary, these observations suggest that RET/PTC is able to phosphorylate the Y315 residue of PKB, an event that results in maximal activation of PKB for RET/PTC-induced thyroid tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994200     DOI: 10.1210/me.2005-0122

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  15 in total

1.  The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Authors:  Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

Review 2.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

3.  Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.

Authors:  Poorni M Manohar; Lauren J Beesley; Jeremy Mg Taylor; Elizabeth Hesseltine; Megan R Haymart; Nazanene H Esfandiari; David A Hanauer; Francis P Worden
Journal:  J Thyroid Disord Ther       Date:  2015-07-17

4.  Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer.

Authors:  Yuwen Li; Keum-Jin Yang; Jongsun Park
Journal:  World J Biol Chem       Date:  2010-08-26

5.  Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor.

Authors:  Yu Zheng; Maoyu Peng; Zebin Wang; John M Asara; Angela L Tyner
Journal:  Mol Cell Biol       Date:  2010-07-06       Impact factor: 4.272

6.  BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.

Authors:  Anna Guerra; Vincenzo Marotta; Maurilio Deandrea; Manuela Motta; Paolo Piero Limone; Alessia Caleo; Pio Zeppa; Silvano Esposito; Franco Fulciniti; Mario Vitale
Journal:  Endocrine       Date:  2012-12-01       Impact factor: 3.633

Review 7.  Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.

Authors:  John E Paes; Matthew D Ringel
Journal:  Endocrinol Metab Clin North Am       Date:  2008-06       Impact factor: 4.741

8.  Phosphorylation site mapping of endogenous proteins: a combined MS and bioinformatics approach.

Authors:  Jeffrey M Sundstrom; Christopher J Sundstrom; Scott A Sundstrom; Patrice E Fort; Richard L H Rauscher; Thomas W Gardner; David A Antonetti
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

9.  KinView: a visual comparative sequence analysis tool for integrated kinome research.

Authors:  Daniel Ian McSkimming; Shima Dastgheib; Timothy R Baffi; Dominic P Byrne; Samantha Ferries; Steven Thomas Scott; Alexandra C Newton; Claire E Eyers; Krzysztof J Kochut; Patrick A Eyers; Natarajan Kannan
Journal:  Mol Biosyst       Date:  2016-11-15

10.  New targeted molecular therapies for dedifferentiated thyroid cancer.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Silvia Martina Ferrari; Marco Sebastiani; Michele Colaci; Ilaria Ruffilli; Poupak Fallahi
Journal:  J Oncol       Date:  2010-06-06       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.